Floatz logo

Poly(Acetyl, Arginyl)Glucosamine (25000-50000 Mw)

Burkholderia Infectious Disease

Synspira, Inc.OtherPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Burkholderia Infectious Disease cohort.

Asset / SponsorPhaseRating
Ceftolozane
Sunshine Coast Hospital and Health Service
Phase 4BB
Tazobactam
Sunshine Coast Hospital and Health Service
Phase 4BB
Aztreonam Lysine
Gilead Sciences
Phase 3BB
Alginate Oligosaccharide
AlgiPharma AS
Phase 2NR

Same molecule, other indications

Poly(Acetyl, Arginyl)Glucosamine (25000-50000 Mw) is also rated in:

respiratory system disorderDormant
CC
Indicative · Phase 1
43 / 100
View asset →
pneumonitisDormant
CC
Indicative · Phase 1
43 / 100
View asset →
pneumoniaDormant
CC
Indicative · Phase 1
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →